Tecentriq Archives -

Doctor in white rubber protective gloves putting adhesive bandage on young man's arm after scratch on skin or injection of vaccine. First aid. Medical, pharmacy and healthcare concept. Closeup.

News/ News/ News/ Oncology/ R&D

Roche scores phase 3 win for subcutaneous Tecentriq, eyes filings

Phil Taylor drug delivery, immuno-oncology, Oncology, Roche, Tecentriq 0 Comment

Roche’s Tecentriq could become the first drug in the PD-1/PD-L1 inhibitor class to be approved in a subcutaneous

Roche scores phase 3 win for subcutaneous Tecentriq, eyes filings

https://pharmaphorum.com/news/roche-scores-phase-3-win-for-subcutaneous-tecentriq-eyes-filings/

News/ News/ Oncology

Roche’s Tecentriq extends lead over Keytruda in adjuvant NSCLC

Phil Taylor adjuvant, immuno-oncology, Keytruda, Merck & Co, Non-small cell lung cancer, Oncology, regulatory approval, Roche, Tecentriq 0 Comment

While Merck & Co’s Keytruda is the undisputed leader of the non-small cell lung cancer (NSCLC) category, there’s

Roche’s Tecentriq extends lead over Keytruda in adjuvant NSCLC

https://pharmaphorum.com/news/roches-tecentriq-extends-lead-over-keytruda-in-adjuvant-nsclc/

Market Access/ News/ News/ News/ Oncology

NICE finds solution to making Keytruda available for TNBC

Phil Taylor HEOR, Keytruda, market access, Merck & Co, NICE, Roche, Tecentriq, triple negative breast cancer 0 Comment

Around 100 patients in England and Wales with triple negative breast cancer (TNBC) that has spread to other

NICE finds solution to making Keytruda available for TNBC

https://pharmaphorum.com/news/nice-finds-solution-to-making-keytruda-available-for-tnbc/

Market Access/ News/ News/ News/ Oncology

CHMP backs Roche’s lymphoma bispecific mosunetuzumab

Phil Taylor CHMP, immuno-oncology, mosunetuzumab, non-Hodgkin lymphoma, Non-small cell lung cancer, Oncology, Roche, Tecentriq 0 Comment

Roche is on the brink of its first regulatory approval for what could be the first bispecific antibody

CHMP backs Roche’s lymphoma bispecific mosunetuzumab

https://pharmaphorum.com/news/chmp-backs-roches-lymphoma-bispecific-mosunetuzumab/

News/ News/ Oncology

Roche hit by failure of TIGIT drug tiragolumab in lung cancer

Phil Taylor immuno-oncology, Oncology, Roche, Tecentriq, TIGIT, tiragolumab 0 Comment

Roche has suffered a setback with its much-anticipated pairing of anti-TIGIT antibody tiragolumab and PD-L1 inhibitor Tecentriq in

Roche hit by failure of TIGIT drug tiragolumab in lung cancer

https://pharmaphorum.com/news/roche-hit-by-failure-of-tigit-drug-tiragolumab-in-lung-cancer/

News/ News/ Oncology

Merck fights back against Roche in adjuvant lung cancer therapy

Phil Taylor adjuvant, Keytruda, Merck & Co, Non-small cell lung cancer, Roche, Tecentriq 0 Comment

Merck & Co’s Keytruda is poised to move even earlier in the treatment of patients with non-small cell

Merck fights back against Roche in adjuvant lung cancer therapy

https://pharmaphorum.com/news/merck-fights-back-against-roche-in-adjuvant-lung-cancer-therapy/

News/ News/ Oncology

BMS carves out a neoadjuvant niche for Opdivo in NSCLC

Phil Taylor Bristol-Myers Squibb, Keytruda, Merck & Co, Non-small cell lung cancer, Opdivo, Roche, Tecentriq 0 Comment

Bristol-Myers Squibb’s Opdivo has been playing second fiddle to Merck & Co’s Keytruda in the non-small cell lung

BMS carves out a neoadjuvant niche for Opdivo in NSCLC

https://pharmaphorum.com/news/bms-carves-out-a-neoadjuvant-niche-for-opdivo-in-nsclc/

News/ News/ Oncology

Chasing Roche, Merck unveils adjuvant lung cancer data for Keytruda

Phil Taylor adjuvant, Keytruda, Merck & Co, Non-small cell lung cancer, Roche, Tecentriq 0 Comment

Merck & Co’s Keytruda is the undisputed market leader in immunotherapy for non-small cell lung cancer (NSCLC), but

Chasing Roche, Merck unveils adjuvant lung cancer data for Keytruda

https://pharmaphorum.com/news/chasing-roche-merck-unveils-adjuvant-lung-cancer-data-for-keytruda/

News/ News/ Oncology

Roche builds case for TIGIT combo in untreated lung cancer

Phil Taylor immuno-oncology, Non-small cell lung cancer, Oncology, Roche, Tecentriq, TIGIT, tiragolumab 0 Comment

Roche’s closely-watched combination of anti-TIGIT antibody tiragolumab and PD-L1 inhibitor Tecentriq has shown long-term efficacy in an ongoing

Roche builds case for TIGIT combo in untreated lung cancer

https://pharmaphorum.com/news/roche-builds-case-for-tigit-combo-in-untreated-lung-cancer/

Trending

Tecentriq

Login